AIDS Clinical Trials Group

Over recent years, her research has made seminal contributions to the understanding of how midlife transitions impact women's health, spanning metabolic, psychological, vasomotor, and cardiovascular considerations.

She is one of the leadership team for the currently enrolling ACTG trial on menopause in women living with HIV and has recently developed the Her and Now program.

This is an NIH-supported program that worked with women living with HIV to develop educational resources to improve clinician knowledge, comfort, and confidence for providing care to midlife women.

On a personal level, I've had the opportunity to work with Dr. Luby multiple times over the last few years, and I'm always impressed by the clarity of her communication, the depth of her knowledge, and her commitment to improving the lives of women living with HIV.

That really provides an awesome framework for how you could approach discussing therapy and weighing risks and benefits for this particular individual.

You alluded to this, but there is a lack of evidence for MHT specifically in women living with HIV, and there is some effort underway to study that.

Do you want to comment on the study that's currently enrolling in the ACTG that is looking at menopausal hormone therapy?

Yes, we are thrilled to share with you that we recently launched this past spring a study that is funded by the National Institute of Allergy and Infectious Diseases, Division of AIDS, also the ACTG.